NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head Neck Cancers

  • Written by ACN Newswire

image

TOKYO, Jan 7, 2020 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (TSE: 6701), a leader in IT and network technologies, today announced that the first patients have been enrolled in the first-in-human trials evaluating...

Read more: Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian...